| Baricitinib in the Treatment of Adults With Pyoderma Gangrenosum (PG) |
Recruiting |
Pyoderma Gangrenosum|Skin Diseases|Wound Heal|Pyoderma|Skin Ulcer |
NCT04901325 |
| A Study of Baricitinib (LY3009104) in Children With COVID-19 (COV-BARRIER-PEDS) |
Not yet recruiting |
Covid19|Corona Virus Infection |
NCT05074420 |
| Baricitinib Therapy in COVID-19 |
Completed |
COVID|Pneumonia |
NCT04358614 |
| Baricitinib for the Prophylaxis of Graft-Versus-Host Disease After Peripheral Blood Hematopoietic Cell Transplantation |
Recruiting |
Graft-versus-host-disease|Graft Vs Host Disease |
NCT04131738 |
| Baricitinib for coRona Virus pnEumonia (COVID-19): a THerapeutic Trial |
Not yet recruiting |
Corona Virus Infection |
NCT04399798 |
| A Study of Baricitinib (LY3009104) in Adult and Pediatric Japanese Participants With NNS/CANDLE, SAVI, and AGS |
Active, not recruiting |
Nakajo-Nishimura Syndrome|Chronic Atypical Neutrophilic Dermatosis With Lipodystrophy and Elevated Temperature Syndrome|STING-Associated Vasculopathy With Onset in Infancy|Aicardi Goutieres Syndrome |
NCT04517253 |
| A Study of Baricitinib in Healthy Participants |
Completed |
Healthy |
NCT03212638 |
| Safety and Efficacy of Baricitinib for COVID-19 |
Withdrawn |
COVID-19 |
NCT04340232 |
| A Study to Measure Baricitinib (LY3009104) Absorption in Healthy Participants |
Completed |
Healthy Volunteers |
NCT02340104 |
| A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis |
Recruiting |
Juvenile Idiopathic Arthritis |
NCT03773965 |
| A Study of Baricitinib (LY3009104) in Participants With Moderate to Severe Atopic Dermatitis |
Active, not recruiting |
Atopic Dermatitis |
NCT03559270 |
| A Study of Baricitinib (LY3009104) in Adult Participants With Moderate to Severe Atopic Dermatitis |
Completed |
Atopic Dermatitis |
NCT03435081 |
| A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE) |
Recruiting |
Systemic Lupus Erythematosus |
NCT03843125 |
| Study of Baricitinib (LY3009104) in Patients With Moderate to Severe Atopic Dermatitis |
Completed |
Atopic Dermatitis |
NCT03334422 |
| Baricitinib in Patients With Relapsing or naĂŻve Dermatomyositis |
Not yet recruiting |
Dermatomyositis |
NCT04972760 |
| JAK Inhibitor Treatment in AGS |
Active, not recruiting |
Aicardi Goutieres Syndrome |
NCT03921554 |
| A Pharmacokinetic Study of Baricitinib in Participants With Liver Disease |
Completed |
Liver Diseases|Hepatic Insufficiency |
NCT01870388 |
| Baricitinib in Relapsing Giant Cell Arteritis |
Completed |
Arteritis, Giant Cell |
NCT03026504 |
| A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With sJIA |
Recruiting |
Systemic Juvenile Idiopathic Arthritis |
NCT04088396 |
| Efficacy and Safety of Baricitinib in Sjogren's Syndrome |
Not yet recruiting |
Sjogren's Syndrome |
NCT05016297 |
| Effect of Baricitinib Treatment on Peripheral Bone in RA |
Active, not recruiting |
Rheumatoid Arthritis|Bone Density|Finger Joints |
NCT03701789 |
| A Study of Baricitinib and Ciclosporin in Healthy Participants |
Completed |
Healthy Volunteers |
NCT01968057 |
| A Prospective Pilot Study to Explore Efficacy and Safety of Baricitinib in Active Primary Sjogren's Syndrome Patients |
Completed |
Sjogren's Syndrome |
NCT04916756 |
| A Study of Baricitinib (LY3009104) in Participants With COVID-19 |
Completed |
COVID-19 |
NCT04421027 |
| A Study of Baricitinib (LY3009104) in Healthy Chinese Participants |
Completed |
Healthy |
NCT02758613 |
| A Study of Baricitinib and Omeprazole in Healthy Participants |
Completed |
Healthy Volunteers |
NCT01925144 |
| Tocilizumab Versus Baricitinib in Patients With Severe COVID-19 |
Recruiting |
COVID-19 |
NCT05082714 |
| A Study of Baricitinib and Rifampicin in Healthy Participants |
Completed |
Healthy Volunteers |
NCT01910311 |
| Efficacy and Safety of Baricitinib in Patients With Moderate and Severe COVID-19 |
Not yet recruiting |
Covid19 |
NCT05056558 |
| Baricitinib in Symptomatic Patients Infected by COVID-19: an Open-label, Pilot Study. |
Not yet recruiting |
Pharmacological Action |
NCT04320277 |
| A Study of Baricitinib in Healthy Japanese Participants |
Completed |
Healthy Participants |
NCT02263911 |
| A Study of Baricitinib (LY3009104) in Children and Adolescents With Atopic Dermatitis |
Recruiting |
Atopic Dermatitis |
NCT03952559 |
| A Study of Baricitinib in Participants From 2 Years to Less Than 18 Years Old With Juvenile Idiopathic Arthritis |
Active, not recruiting |
Juvenile Idiopathic Arthritis |
NCT03773978 |
| A Study of Baricitinib (LY3009104) in Patients With Moderate to Severe Atopic Dermatitis |
Completed |
Atopic Dermatitis |
NCT03334396 |
| A Study of Baricitinib in Participants With Systemic Lupus Erythematosus |
Completed |
Systemic Lupus Erythematosus |
NCT03616964 |
| A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus |
Completed |
Systemic Lupus Erythematosus |
NCT03616912 |
| A Long-term Study of Baricitinib (LY3009104) With Topical Corticosteroids in Adults With Moderate to Severe Atopic Dermatitis That Are Not Controlled With Cyclosporine or for Those Who Cannot Take Oral Cyclosporine Because it is Not Medically Advisable |
Active, not recruiting |
Atopic Dermatitis |
NCT03428100 |
| A Study of Baricitinib (LY3009104) in Participants From 2 Years to Less Than 18 Years Old With Active JIA-Associated Uveitis or Chronic Anterior Antinuclear Antibody-Positive Uveitis |
Recruiting |
Uveitis |
NCT04088409 |
| A Study of Baricitinib (LY3009104) in Adults With Severe or Very Severe Alopecia Areata |
Active, not recruiting |
Alopecia Areata |
NCT03899259 |
| Baricitinib in New-onset Type 1 Diabetes |
Recruiting |
Type 1 Diabetes |
NCT04774224 |
| Study of Baricitinib, a JAK1/2 Inhibitor, in Chronic Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation |
Active, not recruiting |
Chronic Graft vs Host Disease|Chronic Graft-Versus-Host Disease |
NCT02759731 |
| A Study of Baricitinib in Participants With Rheumatoid Arthritis |
Recruiting |
Rheumatoid Arthritis |
NCT04086745 |
| A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus (SLE) |
Completed |
Systemic Lupus Erythematosus |
NCT02708095 |
| Exploiting Leading Edge 7T MRI Brain Imaging to Decipher Olumiant's Mode of Analgesic Action in Rheumatoid Arthritis |
Recruiting |
Rheumatoid Arthritis |
NCT05112120 |
| A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia Areata |
Active, not recruiting |
Alopecia Areata |
NCT03570749 |
| A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis |
Active, not recruiting |
Rheumatoid Arthritis |
NCT03915964 |
| A Study of Baricitinib and Probenecid in Healthy Participants |
Completed |
Healthy Volunteers |
NCT01937026 |
| A Study of Baricitinib and Birth Control Pills in Healthy Females |
Completed |
Healthy Volunteers |
NCT01896726 |
| A Drug Drug Interaction (DDI) Study of Baricitinib (LY3009104) and Digoxin in Healthy Participants |
Completed |
Healthy Volunteers |
NCT01859078 |
| A Study of Baricitinib When Administered With Ketoconazole or Fluconazole in Healthy Participants |
Completed |
Healthy Volunteers |
NCT01924299 |
| Combination of Baricitinib and Adalimumab in Rheumatoid Arthritis |
Recruiting |
Rheumatoid Arthritis |
NCT04870203 |
| A Phase 2b Study of Baricitinib in Participants With Moderate to Severe Psoriasis |
Completed |
Psoriasis|Skin Diseases|Skin Diseases, Papulosquamous |
NCT01490632 |
| Baricitinib Compared to Standard Therapy in Patients With COVID-19 |
Not yet recruiting |
Covid-19|SARS-CoV 2|SARS Pneumonia |
NCT04393051 |
| A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis (RA) |
Completed |
Rheumatoid Arthritis |
NCT02265705 |
| A Study of Baricitinib (LY3009104) in Participants With Primary Biliary Cholangitis Who do Not Respond or Cannot Take UDCA |
Terminated |
Primary Biliary Cholangitis |
NCT03742973 |
| Efficacy of Baricitinib In Treatment of Delayed-Type Hypersensitivity Versus Irritant Skin Reactions in Healthy Adult Male Subjects |
Recruiting |
Allergic Contact Dermatitis |
NCT03945760 |
| A Study of Baricitinib (LY3009104) in Combination With Topical Corticosteroids in Adults With Moderate to Severe Atopic Dermatitis |
Completed |
Atopic Dermatitis |
NCT03733301 |
| Efficacy of Ramdicivir and Baricitinib for the Treatment of Severe COVID 19 Patients |
Recruiting |
Covid19|Covid-19 ARDS |
NCT04693026 |
| Baricitinib in Hospitalized Covid-19 Patients With Diabetes Mellitus |
Recruiting |
COVID-19 Pneumonia |
NCT04970719 |
| Evaluation of Effect and Tolerance of the Association of Baricitinib and Phototherapy Versus Phototherapy in Adults With Progressive Vitiligo |
Not yet recruiting |
Vitiligo |
NCT04822584 |
| A Study of Baricitinib and Simvastatin in Healthy Participants |
Completed |
Healthy Volunteers |
NCT01960140 |
| Baricitinib, Placebo and Antiviral Therapy for the Treatment of Patients With Moderate and Severe COVID-19 |
Terminated |
Symptomatic COVID-19 Infection Laboratory-Confirmed |
NCT04373044 |
| A Study of Long-term Baricitinib (LY3009104) Therapy in Atopic Dermatitis |
Active, not recruiting |
Atopic Dermatitis |
NCT03334435 |
| A Study of Baricitinib (LY3009104) in Participants With Moderate-to-Severe Atopic Dermatitis |
Completed |
Atopic Dermatitis |
NCT02576938 |
| Disposition of 14C-LY3009104 Following Oral Administration in Healthy Human Subjects |
Completed |
Healthy Volunteers |
NCT01299285 |
| A Moderate to Severe Rheumatoid Arthritis Study |
Completed |
Rheumatoid Arthritis |
NCT01721044 |
| Bioequivalence Study of Baricitinib From Barcimiant 4 mg Film Coated Tablets (Horus Pharma, Egypt) and Olumiant 4 mg Film Coated Tablets (Eli Lilly Nederland B.V., The Netherlands) |
Completed |
Healthy |
NCT05006768 |
| A Study to Test Safety and Efficacy of Baricitinib in Participants With Diabetic Kidney Disease |
Completed |
Diabetic Kidney Disease |
NCT01683409 |
| Factorial Randomized Trial of Rendesivir and Baricitinib Plus Dexamethasone for COVID-19 (the AMMURAVID Trial) |
Not yet recruiting |
Covid19 |
NCT04832880 |
| An Extension Study in Participants With Moderate to Severe Rheumatoid Arthritis |
Completed |
Rheumatoid Arthritis |
NCT01885078 |
| Examination of Efficacy and Safety of Baricitinib in RA Patients |
Recruiting |
Rheumatoid Arthritis |
NCT03755466 |
| BAriCitinib Healing Effect in earLy pOlymyalgia Rheumatica |
Recruiting |
Polymyalgia Rheumatic (PMR) |
NCT04027101 |
| A Study of LY3009104(Baricitinib) for Healthy Subjects |
Completed |
Healthy Volunteer |
NCT01247350 |
| JAK 1/2 Inhibitor, Baricitinib, in the Treatment of Adult IIM |
Recruiting |
Idiopathic Inflammatory Myopathies |
NCT04208464 |
| A Study of LY3009104 in Healthy Participants |
Completed |
Healthy Participants |
NCT01536951 |
| A Study in Participants With Moderate to Severe Rheumatoid Arthritis |
Completed |
Rheumatoid Arthritis |
NCT01711359 |
| Oral Baricitinib (LY3009104)Treatment in Japanese Participants With Active Rheumatoid Arthritis on Background Methotrexate Therapy |
Completed |
Arthritis, Rheumatoid |
NCT01469013 |
| A Study in Moderate to Severe Rheumatoid Arthritis Participants |
Completed |
Rheumatoid Arthritis |
NCT01721057 |
| A Study in Moderate to Severe Rheumatoid Arthritis |
Completed |
Rheumatoid Arthritis |
NCT01710358 |
| INCB028050 Compared to Background Therapy in Patients With Active Rheumatoid Arthritis (RA) With Inadequate Response to Disease Modifying Anti-Rheumatic Drugs |
Completed |
Rheumatoid Arthritis |
NCT00902486 |
| Clinical Trial to Evaluate Efficacy of 3 Types of Treatment in Patients With Pneumonia by COVID-19 |
Active, not recruiting |
COVID-19 Pneumonia |
NCT04346147 |
| Clinical-epidemiological Characterization of COVID-19 Disease in Hospitalized Older Adults |
Completed |
COVID-19 |
NCT04362943 |
| A Relative Bioavailability and Food Effect Study of New Formulations |
Completed |
Chronic Inflammatory Disorder|Arthritis, Rheumatoid |
NCT01398475 |
| mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Repurposed Drugs (TACTIC-R) |
Recruiting |
COVID19 |
NCT04390464 |
| EU SolidAct: An Adaptive Pandemic and Emerging Infection Platform Trial |
Recruiting |
COVID-19|Emerging Infectious Disease |
NCT04891133 |
| Adaptive COVID-19 Treatment Trial 2 (ACTT-2) |
Completed |
COVID-19 |
NCT04401579 |
| A Study in Participants With Rheumatoid Arthritis on Background Methotrexate Therapy |
Completed |
Arthritis, Rheumatoid |
NCT01185353 |
| Adaptive COVID-19 Treatment Trial 4 (ACTT-4) |
Completed |
COVID-19 |
NCT04640168 |
| Treatment of Moderate to Severe Coronavirus Disease (COVID-19) in Hospitalized Patients |
Recruiting |
COVID-19 |
NCT04321993 |
| Compassionate Use Protocol for the Treatment of Autoinflammatory Syndromes |
No longer available |
Chronic Atypical Neutrophilic Dermatosis With Lipodystrophy and Elevated Temperature (CANDLE)|Juvenile Dermatomyositis (JDM)|Stimulator of Interferon Genes (STING)-Associated Vasculopathy With Onset During Infancy (SAVI)|Aicardi-Goutières Syndrome (AGS) |
NCT01724580 |
| Comparative Effectiveness of Targeted Therapy in RA Patients |
Recruiting |
Rheumatoid Arthritis |
NCT04449224 |
| Clinical Trial to Evaluate the Efficacy of Different Treatments in Patients With COVID-19 |
Recruiting |
SARS-CoV-2 Infection |
NCT04890626 |
| Randomised Evaluation of COVID-19 Therapy |
Recruiting |
Severe Acute Respiratory Syndrome |
NCT04381936 |
| Splenic Stimulation for RA |
Recruiting |
Rheumatoid Arthritis |
NCT05003310 |
| Microbiome in Atopic Dermatitis Under Systemic Therapy |
Recruiting |
Atopic Dermatitis |
NCT05099315 |
| Screening for Flare After b/tsDMARD Discontinuation in Rheumatoid Arthritis |
Not yet recruiting |
Rheumatoid Arthritis |
NCT05119452 |
| Effects of Antirheumatic Treatment on Levels of Survivin in Rheumatoid Arthritis Patients |
Recruiting |
Rheumatoid Arthritis |
NCT03440892 |
| Effect of Treatments in Patients Hospitalized for Severe COVID-19 Pneumonia: a Multicenter Cohort Study |
Recruiting |
Covid-19|ARDS|Pneumonia |
NCT04365764 |
| Factors Associated With Clinical Outcomes in Patients Hospitalized for Covid-19 in GHT-93 Est |
Recruiting |
COVID|SARS-CoV 2 |
NCT04366206 |
| Effect of Antiinflammatory Treatment Versus Hand Training on Neuropsychiatric Comorbidity in RA-patients |
Recruiting |
Rheumatoid Arthritis|Pain|Fatigue|Cognitive Decline|Depression|Brain Diseases|Hand Rheumatism |
NCT04378621 |
| Evaluation of Pain Sensitization in Rheumatoid Arthritis: Analysis on a Cohort of Tofacitinib Treated Patients |
Recruiting |
Rheumatoid Arthritis |
NCT03815578 |
| Microbiota Analysis to Predict Outcomes of Rheumatoid Arthritis Patients Treated With JAK-inhibitor |
Recruiting |
Rheumatoid Arthritis |
NCT04530305 |
| Molecular Signatures in Inflammatory Skin Disease |
Recruiting |
Atopic Dermatitis|Psoriasis |
NCT03358693 |
| Results in Real Clinical Practice of Treatment of Moderate-severe Atopic Dermatitis |
Recruiting |
Dermatitis, Atopic |
NCT05078294 |
| JAKPOT (JAK Inhibitors and Predictors of Outcome in rheumaToid Arthritis) |
Recruiting |
Rheumatoid Arthritis |
NCT04084223 |
| Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response |
Recruiting |
Rheumatoid Arthritis |
NCT03414502 |
| Immunopathology of Polymyalgia Rheumatica on Shoulder Bursae's Biopsies |
Not yet recruiting |
Polymyalgia Rheumatica |
NCT04727879 |
